HeartBeam Receives FDA Setback on ECG Software Application
HeartBeam receives NSE letter from FDA for 12-Lead ECG software but plans alternative product launch with already-cleared 3D ECG system.
/ 1666 items
#XY↓
Sangamo Moves Forward with Gene Therapy for Fabry Disease
Sangamo Therapeutics receives FDA approval to submit rolling application for ST-920, a one-time gene therapy treating Fabry disease, with accelerated review pathway granted.
GSK and AnaptysBio Enter Legal Battle Over Cancer Drug Jemperli
GSK subsidiary Tesaro and AnaptysBio file dueling lawsuits in Delaware court over alleged breaches of their 2014 Jemperli licensing agreement, with trial set for July 2026.
Mizuho Starts Coverage on Tarsus Pharmaceuticals With Bullish $100 Target
Mizuho initiates coverage on Tarsus Pharmaceuticals with an Outperform rating and a $100 price target, citing strong prospects for Xdemvy and projected peak sales above $2B.
Cantor Fitzgerald Starts Coverage on Lexeo Therapeutics with Strong Outlook
Cantor Fitzgerald initiates coverage of Lexeo Therapeutics with an Overweight rating, praising its cardiac gene therapy programs and transparent updates.
Nuvation Bio Soars on Ibtrozi Success and Analyst Upgrades
Nuvation Bio shares jump 49% Wed. after strong Ibtrozi results and analyst upgrades, signaling growth potential in biotech and cancer treatments.